Correlation between insulin-like growth factor binding protein-3 serum level and XXXX progression.

@entity1 @entity320 @entity2301
BACKGROUND: @entity2301 is the main carrier of circulating IGFs and the main modulator of their activity. @entity2301 controls cellular availability of IGFs, which cannot exert their pro-proliferative activity while bound to @entity2301 . Proteolysis of @entity2301 is one mechanism to control IGF release. A reduction of serum @entity2301 levels and the associated increased availability of IGFs may represent a strategy whereby @entity320 increases its metastatic potential. OBJECTIVE: The aim of our study was to evaluate the correlation between the @entity2301 serum level and @entity320 stage. METHODS: The study included 41 @entity1 , 24 male and 17 female, with median age of 60 years (range 24-80), affected by @entity320 . Blood samples were taken from each @entity1 and @entity2301 serum levels were measured using Western blot analysis with commercial antibodies. Values were normalized using commercial @entity2301 . RESULTS: The statistical analysis showed that full-size, glycosylated @entity2301 concentrations were significantly lower in the sera of @entity1 with stage IV @entity320 . Low serum levels of @entity2301 correlated with both disease progression and presence of disease at the time of sample collection. In @entity1 who underwent follow-up visits with further collections of blood samples, the concentrations of glycosylated @entity2301 decreased only in those who showed progression of disease. LIMITATIONS: Our study shows only preliminary results on a limited number of @entity1 . CONCLUSION: We demonstrate that there is a significant inverse correlation between the serum concentration of full-size, glycosylated @entity2301 and disease progression in @entity1 with @entity320 .
